Expanded Access to Venetoclax
- Sponsor
- AbbVie
- Study ID
- NCT03123029
- Status
- Available
Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)
- Amyloidosis
- Chronic Lymphocytic Leukemia (CLL)
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
- Plasma Cell Leukemia
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Venetoclax — DRUGVenetoclax will be administered orally.
Study Details
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Key Dates
- Status verified
- Apr 2025
Central Contacts
- ABBVIE CALL CENTER844-663-3742
Related Studies
- Establishing a Tumor Bank in Families With Multiple Lymphoproliferative MalignanciesRecruiting · Dana-Farber Cancer Institute · Boston, Massachusetts
- Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative DisordersRecruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
- Family Study of Lymphoproliferative DisordersRecruiting · Mayo Clinic · Rochester, Minnesota
- Collection of Samples and Clinical Data From Patients With Amyloid DiseasesRecruiting · Boston Medical Center · Boston, Massachusetts